Alx Oncology Holdings (ALXO) Net Cash Flow Growth (1y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 198.34% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 467.41% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14,223.53% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 453.08% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -125.22% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.46% |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 422.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 422.19% |
| Dec 31, 2025 | -582.53% |
| Sep 30, 2025 | 628.87% |
| Jun 30, 2025 | -187.88% |
| Mar 31, 2025 | 136.43% |
| Dec 31, 2024 | -48.09% |
| Sep 30, 2024 | 103.08% |
| Jun 30, 2024 | 105.94% |
| Mar 31, 2024 | -158.20% |
| Dec 31, 2023 | 1,316.38% |
| Sep 30, 2023 | -6.53% |
| Jun 30, 2023 | 72.87% |
| Mar 31, 2023 | 107.03% |
| Dec 31, 2022 | 98.92% |
| Sep 30, 2022 | 30.19% |
| Jun 30, 2022 | -366.08% |
| Mar 31, 2022 | -4,586.41% |
| Dec 31, 2021 | -112.29% |
| Sep 30, 2021 | -115.38% |
| Jun 30, 2021 | -186.94% |
| Mar 31, 2021 | -104.54% |
| Dec 31, 2020 | 5,509.47% |
| Sep 30, 2020 | 5,165.32% |